Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-22-029905

Chief R&D Officer sold 21,673 shares at $3.95 ($85,608)

  • Chief R&D Officer acquired 23,950 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Zalevsky Jonathan Chief R&D Officer 2022-05-15 Grant or award +23,950 298,072 D
Zalevsky Jonathan Chief R&D Officer 2022-05-16 Sale −21,673 $3.95 $85,608 276,399 D
Open-market sales · 21,673 sh · avg $3.95 · $85,608
Loading xslF345X03/doc4.xml…